全文获取类型
收费全文 | 21803篇 |
免费 | 1758篇 |
国内免费 | 419篇 |
专业分类
耳鼻咽喉 | 144篇 |
儿科学 | 581篇 |
妇产科学 | 396篇 |
基础医学 | 1954篇 |
口腔科学 | 481篇 |
临床医学 | 2298篇 |
内科学 | 5515篇 |
皮肤病学 | 290篇 |
神经病学 | 1041篇 |
特种医学 | 1047篇 |
外科学 | 1991篇 |
综合类 | 2047篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 2565篇 |
眼科学 | 534篇 |
药学 | 1704篇 |
7篇 | |
中国医学 | 337篇 |
肿瘤学 | 1046篇 |
出版年
2024年 | 17篇 |
2023年 | 801篇 |
2022年 | 1070篇 |
2021年 | 1839篇 |
2020年 | 1486篇 |
2019年 | 1641篇 |
2018年 | 1503篇 |
2017年 | 981篇 |
2016年 | 677篇 |
2015年 | 716篇 |
2014年 | 1611篇 |
2013年 | 1391篇 |
2012年 | 950篇 |
2011年 | 1079篇 |
2010年 | 891篇 |
2009年 | 826篇 |
2008年 | 897篇 |
2007年 | 831篇 |
2006年 | 628篇 |
2005年 | 549篇 |
2004年 | 415篇 |
2003年 | 406篇 |
2002年 | 306篇 |
2001年 | 248篇 |
2000年 | 203篇 |
1999年 | 183篇 |
1998年 | 137篇 |
1997年 | 121篇 |
1996年 | 146篇 |
1995年 | 135篇 |
1994年 | 110篇 |
1993年 | 105篇 |
1992年 | 121篇 |
1991年 | 85篇 |
1990年 | 107篇 |
1989年 | 91篇 |
1988年 | 90篇 |
1987年 | 49篇 |
1986年 | 61篇 |
1985年 | 79篇 |
1984年 | 73篇 |
1983年 | 40篇 |
1982年 | 50篇 |
1981年 | 43篇 |
1980年 | 39篇 |
1979年 | 37篇 |
1978年 | 23篇 |
1977年 | 29篇 |
1976年 | 15篇 |
1974年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
《Journal of vascular and interventional radiology : JVIR》2022,33(11):1301-1312.e13
PurposeTo assess the critical role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of Budd-Chiari syndrome (BCS), as the data with respect to the safety and outcome of TIPS in patients with BCS are scarce because of the rarity of the disease.Materials and MethodsA comprehensive search of literature of various databases from 2000 to October 2021 was conducted for studies evaluating the outcome of TIPS in patients with BCS. The primary outcomes of the analysis were technical and clinical success, adverse events and mortality associated with TIPS, dysfunction of TIPS, need for TIPS revision, need for liver transplantation (LT), and 1-year survival.ResultsA total of 33 studies (1,395 patients) were included in this meta-analysis. The pooled rates and 95% confidence intervals of various outcomes were 98.6% (97.6–99.7) for technical success, 90.3% (86.0–94.6) for clinical success, 10.0% (6.5–13.6) for major adverse events, 0.5% (0.2–1.0) for TIPS-related mortality, 11.6% (7.8–15.4) for post-TIPS hepatic encephalopathy (HE), 40.1% (32.5–47.7) for TIPS dysfunction, 8.6% (4.9–12.4) for the need for TIPS revision, 4.5% (2.8–6.2) for the need for LT, and 94.6% (93.1–96.1) for 1-year survival. Publication bias was seen with all outcomes except for post-TIPS HE, TIPS dysfunction, and the need for LT.ConclusionsThe existing literature supports the feasibility, safety, and efficacy of TIPS in the treatment of BCS. Deciding the optimal timing of TIPS in BCS needs further studies. 相似文献
32.
目的:探讨中性粒细胞/淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)对初治前弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)患者预后的意义。方法:回顾性分析2010年1月至2019年10月,新疆医科大学附属肿瘤医院收治的165例初治DLBCL患者,确定了NLR(>2.77)在预后预测中的最佳临界值,采用Log-rank检验和Cox回归模型进行分析,评价治疗前NLR对无进展生存期(progression free survival time,PFS)和总生存期(overall survival rate,OS)的影响。结果:在入选的165例患者中,有67例患者治疗前NLR升高(>2.77),NLR升高与PFS和OS较短的患者明显相关(P<0.001和P=0.003)。多变量分析进一步表明,NLR>2.77是PFS的独立预测因子。结论:治疗前NLR升高提示DLBCL患者预后不良。 相似文献
33.
《Human immunology》2022,83(12):803-807
We examined the correlation between class I HLA evolutionary divergence (HED), a surrogate for the capacity to present different peptides, and the outcomes of 234 adult inpatients with confirmed SARS-CoV-2 infection. Genomic DNA was extracted from peripheral blood and genotyped by next-generation sequencing (NGS). HED scores for HLA class I (HLA-A, -B, and -C) genotypes were calculated using Grantham’s distance. Higher HED scores for HLA-B, but not HLA-A or -C, are significantly associated with a decreased probability of poor outcomes including ICU admission, mechanical ventilation, and death (OR = 0.93; P = 0.04) in the univariate analysis. In the multivariate analysis, increased HLA-B HED score, younger age, and no comorbidity were independently associated with favorable outcomes (P = 0.02, P = 0.01, and P = 0.05, respectively). This finding is consistent with the notion that broader peptide repertoires presented by class I HLA may be beneficial in infection control. 相似文献
34.
《The Journal of thoracic and cardiovascular surgery》2023,165(2):591-604.e3
ObjectivesGuidelines suggest aortic valve replacement (AVR) for low-risk asymptomatic patients. Indications for transcatheter AVR now include low-risk patients, making it imperative to understand state-of-the-art surgical AVR (SAVR) in this population. Therefore, we compared SAVR outcomes in low-risk patients with those expected from Society of Thoracic Surgeons (STS) models and assessed their intermediate-term survival.MethodsFrom January 2005 to January 2017, 3493 isolated SAVRs were performed in 3474 patients with STS predicted risk of mortality <4%. Observed operative mortality and composite major morbidity or mortality were compared with STS-expected outcomes according to calendar year of surgery. Logistic regression analysis was used to identify risk factors for these outcomes. Patients were followed for time-related mortality.ResultsWith 15 observed operative deaths (0.43%) compared with 55 expected (1.6%), the observed:expected ratio was 0.27 for mortality (95% confidence interval [CI], 0.14-0.42), stroke 0.65 (95% CI, 0.41-0.89), and reoperation 0.50 (95% CI, 0.42-0.60). Major morbidity or mortality steadily declined, with probabilities of 8.6%, 6.7%, and 5.2% in 2006, 2011, and 2016, respectively, while STS-expected risk remained at approximately 12%. Mitral valve regurgitation, ventricular hypertrophy, pulmonary, renal, and hepatic failure, coronary artery disease, and earlier surgery date were residual risk factors. Survival was 98%, 91%, and 82% at 1, 5, and 9 years, respectively, superior to that predicted for the US age-race-sex–matched population.ConclusionsSTS risk models overestimate contemporary SAVR risk at a high-volume center, supporting efforts to create a more agile quality assessment program. SAVR in low-risk patients provides durable survival benefit, supporting early surgery and providing a benchmark for transcatheter AVR. 相似文献
35.
舌癌患者手术及放化疗后会出现构音障碍、吞咽困难、口腔黏膜炎、口干、营养不良等并发症,使患者生存质量下降,甚至导致肿瘤的复发转移,影响生存期,单一方法往往顾此失彼。依托于中国中医科学院西苑医院肿瘤康复基地,杨宇飞教授在国内外调研考察基础上,结合中国国情,构建了一种“门诊多学科肿瘤康复模式”,在舌癌康复方面,以患者为中心,以中医肿瘤内科为主导,多学科共同参与,结合康复科、口腔科、营养科、药剂科等各科优势,形成全程个体化规范序贯康复方案,对患者及早进行康复,在放疗前进行预防性干预尤其重要,使患者能够快速缓解手术和放疗的不良反应,患者获益明显。现取两个典型案例总结其舌癌多学科康复的经验,以期为舌癌的康复提供借鉴。 相似文献
36.
37.
38.
39.
40.